Relevance of Chronic Total Occlusion for Outcome of Ventricular Tachycardia Ablation in Ischemic Cardiomyopathy

Table 3

Outcome predictors non-CTO patients.

	Univariable HR (95% CI)	value	Multivariable HR (95% CI)	value
Age		0.16
Female sex	0.63 (0.23–1.78)	0.36
BMI	1.10 (0.80–1.50)	0.55
Diabetes mellitus	0.62 (0.29–1.30)	0.62
Hypertension	2.64 (0.64–10.96)	0.12
Renal dysfunction (GFR ≤ 60 ml/min)	1.91 (1.02–3.56)	0.043
Multivessel disease	0.82 (0.44–1.53)	0.54
Coronary artery bypass graft	0.58 (0.23–1.48)	0.25
NYHA III or IV	2.27 (1.21–4.24)	0.10
ICD on admission	0.45 (0.21–0.97)	0.041
Amiodarone on admission	1.20 (0.57–2.52)	0.64
Ventricular tachycardia cycle length	1.00 (0.99–1.01)	0.67
LVEF per 10%	0.96 (0.52–0.92)	0.006	0.52–0.92	0.006
LV end-diastolic diameter	1.00 (0.98–1.03)	0.79

Confidence interval = CI; hazard ratio = HR; implantable cardioverter-defibrillator (ICD); glomerular filtration rate = GFR; left ventricular ejection fraction = LVEF; New York Heart Association = NYHA.